ADVERTISEMENT

Recurrent endometrial cancer: letrozole-abemaciclib shows durable response

Deepa Koli   |   Clinical Summary   |   10 October 2022
ADVERTISEMENT

Takeaway

  • Letrozole in combination with abemaciclib is safe and shows durable response in women with recurrent estrogen receptor-positive endometrioid endometrial cancer, including those who had previously received hormonal therapy.

Why this matters

  • These results suggest that letrozole-abemaciclib is not cross-resistant with other hormonal approaches and may represent a viable salvage endocrine...

          

January Challenge

Ends in 2d 14h
left
right

Topic Challenges

left
right